Teva Pharmaceutical Industries has been granted a patent for an inhaler design featuring a lock system for securing the cap housing to the main body. The inhaler includes a canister with pressurized inhalable substances and a metering valve for precise dosing. The unique helical thread lock system ensures a secure snap lock mechanism. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of February 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Inhaler with lock system for inhalable substances
A recently granted patent (Publication Number: US11896759B2) discloses an inhaler designed for the inhalation of inhalable substances. The inhaler comprises a main body and a cap housing with an interior chamber that encloses a canister containing pressurized inhalable substances. The inhaler features a unique lock system with helical threads and lock members that provide rotational attachment of the cap housing to the main body, ensuring a secure snap lock when in a locked position. The lock system is designed to resist both longitudinal movement and rotation between the cap housing and the main body, enhancing the overall functionality and safety of the inhaler.
Furthermore, the patent details various configurations and components of the inhaler, including a metering valve with a communication path for the flow of liquid and gas, a canister fire system for ejecting inhalable substances, and a reset actuator for preventing exposure of the metering chamber to atmosphere. The inhaler also includes features such as a dose counter, actuator system, and a unique design for a nasal inhaler with a nosepiece cap and yoke mechanism. Additionally, the patent specifies release torque requirements for the lock system, ensuring ease of use while maintaining a secure attachment between the main body and cap housing. Overall, the patented inhaler design aims to provide a reliable and efficient device for the administration of inhalable substances, catering to various inhalation needs and preferences.
To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
